SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Edelman Martin J.; Redman Mary W.; Albain Kathy S.; McGary Eric C.; Rafique Noman M.; Petro Daniel; Waqar Saiama N.; Minichiello Katherine; Miao Jieling; Papadimitrakopoulou Vassiliki A.; Kelly Karen; Gandara David R.; Herbst Roy S.

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

【24h】

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

机译：Swog S1400C（NCT02154490）-A-AII研究Palbociclib的先前处理的细胞周期基因改变阳性IV阶段鳞状细胞肺癌（肺部落地）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Objective: Lung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous NSCLC. The objective of study C (S1400C) was to evaluate the response rate to palbociclib, a cyclin-dependent kinase 4 and cyclin-dependent kinase 6 inhibitor, in patients with cell cycle gene abnormalities.

机译：目的：肺部地图（Swog S1400）是一个大型平台试验，评估鳞状NSCLC中的有针对性的疗法。研究C（S1400C）的目的是在细胞周期基因异常的患者中评估对Palbociclib，对依赖性激酶4和细胞周期蛋白依赖性激酶6抑制剂的反应速率。

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2019年第10期|共7页
作者
Edelman Martin J.; Redman Mary W.; Albain Kathy S.; McGary Eric C.; Rafique Noman M.; Petro Daniel; Waqar Saiama N.; Minichiello Katherine; Miao Jieling; Papadimitrakopoulou Vassiliki A.; Kelly Karen; Gandara David R.; Herbst Roy S.;
展开▼
作者单位

Fox Chase Canc Ctr 333 Cottman Ave Philadelphia PA 19111 USA;

Fred Hutchinson Canc Reseach Ctr SWOG Stat &

Data Management Ctr Seattle WA USA;

Loyola Univ Chicago Stritch Sch Med Maywood IL 60153 USA;

Kaiser Permanente Med Grp Kaiser Permanente Natl Community Oncol Res Progra Los Angeles CA USA;

Mercy Med Ctr Tri Cty Hematol Oncol Assoc Canton OH USA;

Univ Pittsburgh Canc Inst Pittsburgh PA USA;

Washington Univ Sch Med St Louis MO USA;

Fred Hutchinson Canc Reseach Ctr SWOG Stat &

Data Management Ctr Seattle WA USA;

Fred Hutchinson Canc Reseach Ctr SWOG Stat &

Data Management Ctr Seattle WA USA;

Univ Texas MD Anderson Canc Ctr Thorac Head &

Neck Med Oncol Houston TX 77030 USA;

Univ Calif Davis Canc Ctr Sacramento CA 95817 USA;

Univ Calif Davis Canc Ctr Sacramento CA 95817 USA;

Yale Canc Ctr Med Oncol New Haven CT USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Lung cancer; Targeted therapy; Squamous NSCLC; Cell cycle gene alteration; Cyclin-dependent kinase; Master protocol;

机译：肺癌;靶向治疗;鳞状NSCLC;细胞周期基因改变;细胞周期依赖性激酶;硕士协议;

相似文献

外文文献
中文文献
专利

1. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) [J] . Edelman Martin J., Redman Mary W., Albain Kathy S., Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第10期

机译：Swog S1400C（NCT02154490）-A-AII研究Palbociclib的先前处理的细胞周期基因改变阳性IV阶段鳞状细胞肺癌（肺部落地）
2. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) [J] . Langer Corey J., Redman Mary W., Wade James L. III, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第10期

机译：SWOG S1400B（NCT02785913），一种用于GDC-0032（Taselisib）的II期研究，用于先前治疗的PI3K阳性阶段阶段鳞状细胞肺癌（肺部地图亚研究）
3. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer [J] . Ciuleanu Tudor, Socinski Mark A., Obasaju Coleman, Clinical lung cancer . 2018,第2期

机译：III期阶段鳞状非小细胞肺癌患者III期桡醛研究的疗效和安全性
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Editors choice: Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized multicenter open-label phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer [O] . L. Paz-Ares, M. A. Socinski, J. Shahidi, -1

机译：编辑选择：SQUIRE中EGFR表达与安全性和疗效结果的相关性：吉西他滨-顺铂加尼妥单抗与单独吉西他滨-顺铂在IV期患者一线治疗中的随机多中心开放标签III期研究鳞状非小细胞肺癌
7. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) [O] . Charu Aggarwal, Mary W. Redman, Primo N. Lara, 2019

机译：Swog S1400D（NCT02965378），该二纤维细胞生长因子受体抑制剂AZD4547在先前治疗的成纤维细胞生长因子途径活化阶段IV鳞状细胞肺癌（肺映射Superdy）中的研究

SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅